← All trials
NCT04370431
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2020
- Primary completion
- Mar 4, 2021
- Completion date
- Aug 4, 2021
- First posted
- May 1, 2020
- Last posted
- May 1, 2020
- Enrollment
- 60
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Auzone Biological Technology Pty LtdLead sponsor
- CMAX Clinical ResearchCollaborator
- Tigermed Consulting Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.